Functional heartburn-persistent symptoms of esophageal refl ux with no objective evidence of gastroesophageal refl ux disease (GERD)-is the most common cause of failure of proton pump inhibitor (PPI) therapy, but it is often overlooked by internists and gastroenterologists.
A 44-year-old woman presents with an 8-year history of intermittent heartburn, and in the past year she has been experiencing her symptoms daily. She says the heartburn is constant and is worse immediately after eating spicy or acidic foods. She says she has had no dysphagia, weight loss, or vomiting. Her symptoms have persisted despite taking a histamine (H) 2 -receptor antagonist twice daily plus a proton pump inhibitor (PPI) before breakfast and dinner for more than 3 months.
She has undergone upper endoscopy 3 times in the past 8 years. Each time, the esophagus was normal with a regular Z-line and normal biopsy results from the proximal and distal esophagus.
The patient believes she has severe gastroesophageal refl ux disease (GERD) and asks if she is a candidate for fundoplication surgery.
■ HEARTBURN IS A SYMPTOM; GERD IS A CONDITION
A distinction should be made between heartburn-the symptom of persistent retrosternal burning and discomfort-and gastroesophageal refl ux disease-the condition in which refl ux of stomach contents causes troublesome symptoms or complications. 1 While many clinicians initially diagnose patients who have heartburn as having GERD, there are many other potential causes of their symptoms. For patients with persistent heartburn, an empiric trial of a once-daily PPI is usually effective, but one-third of patients continue to have heartburn. 2, 3 The most common cause of this PPI-refractory heartburn is functional heartburn, a functional or hypersensitivity disorder of the esophagus. 4 
■ PATHOPHYSIOLOGY IS POORLY UNDERSTOOD
Functional heartburn is defi ned as retrosternal burning in the absence of objective evidence of GERD, mucosal abnormality (ie, erosive esophagitis), or major motility disorder. 5 The symptoms are theorized to result from hypersensitivity of the visceral nerves of the esophagus, which may be exacerbated by central sensitization, hypervigilance, stress, and anxiety. 6 The pathogenesis is poorly understood, but it may involve activation of infl ammatory mediators in the esophagus, alterations in esophageal mucosal integrity, increased chemical and pressure sensation in the esophagus, and both peripheral and central sensitization (Figure 1) . 7 
■ DIAGNOSTIC EVALUATION
When evaluating patients with heartburn symptoms refractory to PPI therapy, the differential diagnosis is broad and includes GERD, eosinophilic esophagitis, infectious esophagitis, pill-induced esophagitis, esophageal motility disorder, and functional heartburn ( Table 1) . Of these, functional heartburn is the most common, accounting for more than 50% of cases of PPI-refractory heartburn. 8 Clinicians have several tests available for diagnosing these conditions.
Upper endoscopy
Upper endoscopy is recommended for patients with heartburn that does not respond to a 3-month trial of a PPI. 9 Endoscopy is also indicated in any patient who has any of the following "alarm symptoms" that could be due to malignancy or peptic ulcer: During upper endoscopy, the esophagus is evaluated for refl ux esophagitis, Barrett esophagus, and other infl ammatory disorders such as infectious esophagitis. But even if the esophageal mucosa appears normal, the proximal and distal esophagus should be biopsied to rule out an infl ammatory disorder such as eosinophilic or lymphocytic esophagitis.
Esophageal manometry
If endoscopic and esophageal biopsy results are inconclusive, a workup for an esophageal motility disorder is the next step. Dysphagia is the most common symptom of these disorders, although the initial presenting symptom may be heartburn or regurgitation that persists despite PPI therapy.
Manometry is used to test for motility disorders such as achalasia and esophageal spasm. 10 After applying a local anesthetic inside the nares, the clinician inserts a fl exible catheter (about 4 mm in diameter) with 36 pressure sensors spaced at 1-cm intervals into the nares and passes it through the esophagus and lower esophageal sphincter. The patient then swallows liquid, and the sensors relay the esophageal response, creating a topographic plot that shows esophageal peristalsis and lower esophageal sphincter relaxation.
Achalasia is identifi ed by incomplete lower esophageal sphincter relaxation combined with 100% failed peristalsis in the body of the esophagus. Esophageal spasms are identifi ed by a shortened distal latency, which corresponds to premature contraction of the esophagus during peristalsis. 11
Esophageal pH testing
Measuring esophageal pH levels is an important step to quantify gastroesophageal refl ux and determine if symptoms occur during refl ux events. According to the updated Porto GERD consensus group recommendations, 12 a pH test is positive if the acid exposure time is greater than 6% of the testing period. Test-ing the pH differentiates between GERD (abnormal acid exposure), refl ux hypersensitivity (normal acid exposure, strong correlation between symptoms and refl ux events), and functional heartburn (normal acid exposure, negative correlation between refl ux events and symptoms). 5 For this test, a pH probe is placed in the esophagus transnasally or endoscopically. The probe records esophageal pH levels for 24 to 96 hours in an outpatient setting. Antisecretory therapy needs to be withheld for 7 to 10 days before the test.
Transnasal pH probe. For this approach, a thin catheter is inserted through the nares and advanced until the tip is 5 cm proximal to the lower esophageal sphincter. (The placement is guided by the results of esophageal manometry, which is done immediately before pH catheter placement.) The tube is secured with clear tape on the side of the patient's face, and the end is connected to a portable recorder that compiles the data. The patient pushes a button on the recorder when experiencing heartburn symptoms. (A nurse instructs the Functional heartburn accounts for > 50% of cases of PPIrefractory heartburn 
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predictor of response to therapy than weakly acid or nonacid refl ux. 12 Wireless pH probe. This method uses a disposable, catheter-free, capsule device to measure esophageal pH. The capsule, about the size of a gel capsule or pencil eraser, is attached to the patient's esophageal lining, usually during upper endoscopy. The capsule records pH levels in the lower esophagus for 48 to 96 hours and transmits the data wirelessly to a receiver the patient wears. The patient pushes buttons on the receiver to record symptom-specifi c data when experiencing heartburn, chest pain, regurgitation, or cough. The capsule detaches from the esophagus spontaneously, generally within 7 days, and is passed out of the body through a bowel movement.
Diagnosing functional heartburn
The Rome IV diagnostic criteria for functional heartburn 5 require that a patient experience retrosternal burning, discomfort, or pain at least twice a week for at least 6 months. By definition, the symptoms have not responded to antisecretory drugs (an H 2 -receptor antagonist or PPI) in optimal doses. Also, infl ammatory disorders such as erosive esophagitis and eosinophilic esophagitis and motility disorders such as achalasia (Table 1) need to be ruled out.
■ CASE CONTINUED: NORMAL RESULTS ON TESTING
The patient undergoes esophageal manometry and esophagogastroduodenoscopy with placement of a wireless pH probe. Results of esophageal manometry are normal. She has normal lower esophageal resting pressure and relaxation and normal peristalsis in the esophagus body ( Figure 2 ). Wireless pH testing shows a total acid exposure time of 1.7% and a strongly negative symptom association with heartburn, chest pain, and regurgitation (Figure 3) . Based on these results, her condition is diagnosed as functional heartburn, consistent with the Rome IV criteria. 5 
■ TREATMENT

Patient education is key
Patient education about the pathogenesis, natural history, and treatment options is the most important aspect of treating any functional gastrointestinal disorder. This includes the "brain-gut connection" and potential mechanisms of dysregulation. Patient education along with assessment of symptoms should be part of every visit, especially before discussing treatment options.
A pH test is positive if the acid exposure time is > 6% Figure 3 . In our patient with functional heartburn, 24-hour wireless esophageal pH testing showed a pH greater than 4 (the conventional cutoff in esophageal pH testing) for most of the test. During the test, the patient recorded experiencing heartburn 67 times (gray diamonds); her esophageal pH was below 4 for just 3 of the 67 events. This pH test is consistent with a diagnosis of functional heartburn. The vertical axis shows the pH from 0 to 8, with a midline at 4. The horizontal axis shows a 24-hour period from noon to noon.
Time
Antidepressants are used because of their effects on serotonin and norepinephrine in the gut
Patients whose condition is diagnosed as functional heartburn need reassurance that the condition is benign and, in particular, that the risk of progression to esophageal adenocarcinoma is minimal in the absence of Barrett esophagus. 13 Also important to point out is that the disorder may spontaneously resolve: resolution rates of up to 40% have been reported for other functional gastrointestinal disorders. 14
Antisecretory medications may work for some
A PPI or H 2 -receptor antagonist is the most common fi rst-line treatment for heartburn symptoms. Although most patients with functional heartburn experience no improvement in symptoms with an antisecretory agent, a small number report some relief, which suggests that acid-suppression therapy may have an indirect impact on pain modulation in the esophagus. 15 In patients who report symptom relief with an antisecretory agent, we suggest continuing the medication tapered to the lowest effective dose, with repeated reassurance that the medication can be discontinued safely at any time.
Antirefl ux surgery should be avoided
Antirefl ux surgery should be avoided in patients with normal pH testing and no objective fi nding of refl ux, as this is associated with worse subjective outcomes than in patients with abnormal pH test results. 16 
Neuromodulators
No drug has yet been approved by the US Food and Drug Administration to treat functional heartburn, and clinical evidence for treating this condition is minimal. Using neuromodulators to reduce pain perception is the mainstay of treatment for functional gastrointestinal disorders, including functional heartburn. Table 2 lists neuromodulators used to treat functional esophageal disorders, with recommended dosing intervals.
It is important to discuss with patients the concept of neuromodulation, including the fact that antidepressants are often used because of their effects on serotonin and norepinephrine, which decrease visceral hypersensitivity.
The selective serotonin reuptake inhibitor citalopram has been shown to reduce esophageal hypersensitivity, 17 and a tricyclic antidepressant has been shown to improve quality of life. 18 These results have led experts to recommend a trial of a low dose of either type of medication. 19 The dose of tricyclic antidepressant often needs to be increased sequentially every 2 to 4 weeks.
Interestingly, melatonin 6 mg at bedtime has also shown effi cacy for functional heartburn, potentially due to its antinociceptive properties. 20
Alternative and complementary therapies
Many esophageal centers use cognitive behavioral therapy and hypnotherapy as fi rstline treatment for functional esophageal disorders. Here again, it is important for the patient to understand the rationale of therapy for functional gastrointestinal disorders, given the stigma in the general population regarding psychotherapy.
Cognitive behavioral therapy has been used for functional gastrointestinal disorders for many years, as it has been shown to modulate visceral 
Serotonin and norepinephrine reuptake inhibitors Venlafaxine Duloxetine
Dosing: Start at lowest dose; increase every 4-6 weeks as needed GABBARD AND VIJAYVARGIYA perception. 21 Although published studies are limited, research regarding other functional esophageal disorders suggests that patients who commit to long-term behavioral therapy have had a signifi cant improvement in symptoms. 22 The goal of esophageal-directed behavioral therapy is to promote focused relaxation using deep breathing techniques, which can help patients manage esophageal hypervigilance, especially if symptoms continue despite neuromodulator therapy. Specifi cally, hypnotherapy has been shown to modulate functional chest pain through the visceral sensory pathway and also to suppress gastric acid secretion. 21, 23 A study of a 7-week hypnotherapy program reported signifi cant benefi ts in heartburn relief and improved quality of life in patients with functional heartburn. 24 The data support the use of behavioral therapies as fi rst-line therapy or as adjunctive therapy for patients already taking a neuromodulator.
■ CASE FOLLOW-UP: IMPROVEMENT WITH TREATMENT
During a follow-up visit, the patient is given several printed resources, including the Rome Foundation article on functional heartburn. 5 We again emphasize the benign nature of functional heartburn, noting the minimal risk of progression to esophageal adenocarcinoma, as she had no evidence of Barrett esophagus on endoscopy. And we discuss the natural course of functional heartburn, including the spontaneous resolution rate of about 40%. For treatment, we present her the rationale for using neuromodulators and reassure her that these medications are for treatment of visceral hypersensitivity, not for anxiety or depression. After the discussion, the patient opts to start amitriptyline therapy at 10 mg every night at bedtime, increasing the dose by 10 mg every 2 weeks until symptoms improve, up to 75-100 mg every day.
After 3 months, the patient reports a 90% improvement in symptoms while on amitriptyline 30 mg every night. She is also able to taper her antisecretory medications once symptoms are controlled. We plan to continue amitriptyline at the current dose for 6 to 12 months, then discuss a slow taper to see if her symptoms spontaneously resolve. ■ ■ REFERENCES
